Skip to main content
National Cancer Prevention Month: Rising Trends and How to Combat Them With Samuel Kareff, Matthew Hadfield, Waqas Haque, and Joseph Kalis
Keira Smith
Expert Analysis
Oncology Data Advisor® · National Cancer Prevention Month: Rising Trends and How to Combat Them In honor of National Cancer Prevention Month 2024, members of the Oncology Data Advisor Editorial Board and Fellows Forum sat down for a panel discussion about the rising incidence of cancer diagnoses, factors contributing to them, and how to counsel patients in light of these emerging trends.  
Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options With Waqas Haque, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
Oncology Data Advisor® · Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.  
Pancreatic Cancer Awareness Month: Improving Early Detection With Joseph Kalis, PharmD, BCOP
Keira Smith
Expert Analysis
Oncology Data Advisor® · Pancreatic Cancer Awareness Month: Improving Early Detection With Joseph Kalis, PharmD, BCOP This November, Oncology Data Advisor is honoring Pancreatic Cancer Awareness Month and helping to raise awareness about early detection in hopes of improving outcomes for patients with this disease. In this interview, Oncology Data Advisor Editorial Board member Joseph Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, explains the challenges related to diagnosis and screening, ongoing efforts to develop better detection methods, and messages for both the public and the health care community for maintaining awareness of pancreatic cancer.  
Appendix Cancer Awareness Month With Thomas Abrams, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Appendix Cancer Awareness Month With Thomas Abrams, MD In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.  
Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma with Kohei Shitara, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.  
Partnering With Patients Through Advocacy With Allison Rosen, MS
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Partnering With Patients Through Advocacy With Allison Rosen At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor, patient advocate, and Director of Project ECHO for the American Cancer Society. Ms. Rosen shares th...
Results of the HERIZON-BTC-01 Trial of Zanidatamab in Biliary Tract Cancers With Shubham Pant, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Results of the HERIZON-BTC-01 Trial of Zanidatamab in Biliary Tract Cancers With Shubham Pant, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Shubham Pant, Associate Professor in the Department of Medical Oncology at MD Anderson Cancer Center, presented the results of HERIZON-BTC-01, a phase 2b trial investigating zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)–amplified biliary tract cancers. Afterwards he spoke with Oncology Data Advisor to share more about the efficacy, safety, and future directions for zanidatamab. 
Exploring the Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer With Josep Tabernero, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Results of the SUNLIGHT Trial in Metastatic Colorectal Cancer: Josep Tabernero, MD, PhD At the recent American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancer Symposium, Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology, presented results of the phase 3 SUNLIGHT trial of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer. In this interview, Dr. Tabernero further elaborates on the significance of this treatment combination and its emerging role in the treatment landscape.  
The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC.  
Cabozantinib/Atezolizumab and the Future of Metastatic Colorectal Cancer Treatment: Thomas Abrams, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD Treatment options are limited for patients with metastatic colorectal cancer who have microsatellite-stable disease, which renders them ineligible for immune checkpoint inhibitor therapy. In a cohort of the COSMIC-021 trial, a team of researchers led by Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical School, investigated the efficacy of cabozantinib plus atezolizumab for this patient population. Dr. Abrams recently presented the trial's results at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. In this interview, he discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.  
World Cancer Research Day With Dr. Thomas Abrams
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Cancer Research Day With Dr. Thomas Abrams On World Cancer Research Day, Dr. Thomas Abrams of Harvard Medical School discussed his career as a gastrointestinal cancer researcher and the progress that has been made in this field.